TG Therapeutics, Inc. Stock News

NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced initial results from the Company's Phase 1 study evaluating azercabtagene zapreleucel (azer-cel), an investigational, allogeneic CD19-directed chimeric antigen receptor (CAR) T-cell therapy, in patients with progressive multiple sclerosis (MS). The data represent the first reported clinical evaluation of ...

NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced several updated poster presentations at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting. The presentations include seven-year follow up data from the ULTIMATE I & II trials, Phase 1 subcutaneous BRIUMVI data, Phase 3 ENHANCE trial data, an update from the ENABLE real world study, and more presentati...

NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of results from a five-year matching-adjusted indirect comparison (MAIC) evaluating long-term relapse activity and disability progression outcomes with BRIUMVI® (ublituximab-xiiy) compared with ocrelizumab and ofatumumab in patients with relapsing multiple sclerosis (RMS). For the analysis...

NEW YORK--(BUSINESS WIRE)---- $TGTX--TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations at the 10th Joint ACTRIMS-ECTRIMS Meeting, also referred to as MSToronto2026, being held October 21-23, 2026, in Toronto, Canada. The presentations include a late-breaking oral presentation highlighting initial results from a Phase 1 study evaluating azer-cel in pati...

TG Therapeutics stock showed technical strength Wednesday, bounding off its 50-day moving average and nearing a breakout on the weekly chart.

Biotech stock TG Therapeutics is building a cup base after a sell-off in early August. It is testing a key moving average.

Top-notch biotech stocks TG Therapeutics and Twist Bioscience took a tumble Monday on mixed second-quarter reports.